The idea of biological warfare strikes even more fear in the human heart than a possible missile attack. Bio-terrorism assumes additional proportions of threat from the fact that it was, previously, largely untreatable. The actual experience with anthrax in the United States demonstrates the chaos which follows any report of a possible biological danger. The strategic value of Emergent BioSolutions Inc. (EBS) has roots in the Company’s effective answer regarding vaccination against anthrax.

Anthrax is just one example of the kind of microbes terrorists can use. Stock investors should therefore evaluate this company in the light of its platform technology. Researchers employed here can rapidly develop immune system supporters for virtually any kind of biological threat.

Another business value of the company’s core competence is the capability to provide cost-effective solutions for infectious diseases in the public health space. This is a health care issue which does not spare any country in the world. Vaccine development is not new, but this company has special strengths in terms of quick responses to emerging threats to human immunity.

The financial performance of the stock is at least as impressive as a qualitative evaluation of its strategic values. Net revenues for the Most Recent Quarter have exceeded the forecasts of most stock analysts. The outlook for the rest of 2008 is promising as well. No other company has an approved vaccine for protection against anthrax. The stock has climbed to more than 50% over the 52-week low before the end of March. The company is one of the top investment choices in the Biotechnology & Drugs Industry.

Let us hear your thoughts below: